November 7, 2023
UNC Health is the only academic healthcare system in North Carolina and the South participating in the randomized trial, which aims to assess the safety and efficacy of a combination immunotherapy for newly diagnosed glioblastoma patients.
July 31, 2023
Researchers in UNC School of Medicine’s Department of Otolaryngology/Head and Neck Surgery and collaborators at Yale Cancer Center and ECOG-ACRIN Cancer Research Group have identified two subtypes of human papillomavirus positive head and neck cancers, giving them a better glimpse into why some patients respond better to treatment than others.
July 6, 2023
Washington, N.C man with squamous cell carcinoma of the tongue experiences positive life-changing results after participating in an induction therapy clinical trial at the UNC School of Medicine.
May 12, 2023
Jennifer S. Smith, PhD, at the UNC Gillings School of Global Public Health, UNC School of Medicine, and UNC Lineberger Comprehensive Cancer Center, led the phase 3 controlled trial, which showed that self-collection kits and scheduling assistance are key for reaching these populations and preventing cervical cancer.
May 11, 2023
The study, called EPITOPE, led by senior author A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine, and contributing author Edwin Kim, MD, MS, associate professor of pediatrics in the Division of Pediatric Allergy and Immunology at the UNC School of Medicine, shows superior results in desensitizing children to peanuts. Results were recently published in the New England Journal of Medicine.
April 7, 2023
Dominique Higgins, MD, PhD, led research into how a specialized diet can induce a new type of programmed cell death to help kill brain tumor cells.
April 3, 2023
Michael Kappelman, MD, MPH, was the lead PI on the clinical trial, which followed nearly 300 children with Crohn’s to evaluate how their conditions changed in response to anti-TNF biologic treatments alone or in combination with a second immune suppressive medication.
February 27, 2023
A four-year clinical trial led by Edwin Kim, MD, at the UNC School of Medicine, has found that an increased dosage of a unique type of peanut allergy immunotherapy continues to show promise for children.
November 21, 2022
A new glioblastoma treatment from Northwest Biotherapeutics improved outcomes for many patients in a phase 3 clinical study, according to a study published in JAMA Oncology. Matt Ewend, MD, in the UNC Department of Neurosurgery and at UNC Lineberger, led the trial site at the N.C. Basnight Cancer Hospital.
January 20, 2022
This study, called IMPACT, was co-led by A. Wesley Burks, MD, CEO of UNC Health and dean of the UNC School of Medicine. Edwin Kim, MD, is co-author on the paper and leads peanut allergy research at the UNC School of Medicine.
January 3, 2022
James F. Howard Jr., MD, professor in the UNC Department of Neurology, was principal investigator of the phase 3 trial for the experimental drug efgartigimod, developed by Belgian pharmaceutical company Argenx.
August 31, 2021
As part of the NIH-sponsored ACTIV-2 clinical trial for COVID-19 outpatients, preliminary data revealed that a new combination monoclonal antibody treatment reduced hospitalizations and death by 78 percent in high-risk patients. ACTIV-2 vice chair David Wohl, MD, leads monoclonal treatment for UNC Health.